Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir and Elbasvir in HCV/HIV Co-infected Patients
NCT03098121Phase 4Completed
- Sponsor
- Taoyuan General Hospital
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of grazoprevir and elbasvir in hepatitis C (HCV), sponsored by Taoyuan General Hospital. Primary endpoint: Sustained Virological Response 12 weeks after the end of therapy. Started Oct 2017; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03098121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098121.